期刊
SCIENCE
卷 333, 期 6044, 页码 843-850出版社
AMER ASSOC ADVANCEMENT SCIENCE
DOI: 10.1126/science.1204839
关键词
-
资金
- National Institute of Allergy and Infectious Diseases, NIH, Department of Health and Human Services, USA [HHSN272200900060C]
- University Grants Committee, Hong Kong [AoE/M-12/06]
- NIH [GM080209]
- Skaggs Institute
- DOE Office of Biological and Environmental Research
- NIH, National Center for Research Resources
- National Institute of General Medical Sciences
Current flu vaccines provide only limited coverage against seasonal strains of influenza viruses. The identification of V(H)1-69 antibodies that broadly neutralize almost all influenza A group 1 viruses constituted a breakthrough in the influenza field. Here, we report the isolation and characterization of a human monoclonal antibody CR8020 with broad neutralizing activity against most group 2 viruses, including H3N2 and H7N7, which cause severe human infection. The crystal structure of Fab CR8020 with the 1968 pandemic H3 hemagglutinin (HA) reveals a highly conserved epitope in the HA stalk distinct from the epitope recognized by the V(H)1-69 group 1 antibodies. Thus, a cocktail of two antibodies may be sufficient to neutralize most influenza A subtypes and, hence, enable development of a universal flu vaccine and broad-spectrum antibody therapies.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据